Taijyu Satoh, Nobuhiro Yaoita, Kotaro Nochioka, Shunsuke Tatebe, Hideka Hayashi, Saori Yamamoto, Haruka Sato, Hiroyuki Takahama, Hideaki Suzuki, Yosuke Terui, Kaito Yamada, Yusuke Yamada, Takumi Inoue, Tatsuo Aoki, Kimio Satoh, Koichiro Sugimura, Satoshi Miyata, Satoshi Yasuda
AIMS: The pathophysiology of pulmonary hypertension (PH) due to left-sided heart disease (Group 2 PH) is distinct from that of other groups of PH, yet there are still no approved therapies that selectively target pulmonary circulation. The increase in pulmonary capillary pressure due to left-sided heart disease is a trigger event for physical and biological alterations of the pulmonary circulation, including the nitric oxide (NO)-soluble guanylate cyclase-cyclic guanosine monophosphate axis...
September 29, 2023: ESC Heart Failure